You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
Johnson and Johnson
Moodys
McKesson

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Patent: 9,745,577

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,745,577
Title:Reducing intron retention
Abstract: Disclosed herein are methods, compositions, polynucleic acid polymers, assays, and kits for inducing processing of a partially processed mRNA transcript to remove a retained intron to produce a fully processed mRNA transcript that encodes a full-length functional form of a protein. Also described herein are methods and compositions for treating a disease or condition characterized by impaired production of a full-length functional form of a protein or for treating a disease or condition characterized by a defective splicing in a subject.
Inventor(s): Vorechovsky; Igor (Southampton, GB), Kralovicova; Jana (Southampton, GB)
Assignee: UNIVERSITY OF SOUTHAMPTON (Southampton, Hampshire, GB)
Application Number:14/741,071
Patent Claims:see list of patent claims

Details for Patent 9,745,577

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial UNIVERSITY OF SOUTHAMPTON (Southampton, Hampshire, GB) 2034-06-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial UNIVERSITY OF SOUTHAMPTON (Southampton, Hampshire, GB) 2034-06-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial UNIVERSITY OF SOUTHAMPTON (Southampton, Hampshire, GB) 2034-06-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Merck
Mallinckrodt
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.